Results 131 to 140 of about 9,243 (198)

Febuxostat may decrease the incidence of COVID-19 infection among patients with gout: a retrospective cohort study. [PDF]

Front Pharmacol
Wang W, Wang SI, Cheng Y, Wang X, Fan Y, Wei JC.   +5 more
europepmc   +1 more source

Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis [PDF]

, 2017
Sollip Kim, Hyun Jung Kim, Hyeong Sik Ahn, Se Won Oh, Kum Hyun Han, Tae Hyun Um, Chong-Rae Cho, Sang Youb Han   +7 more
openalex   +1 more source

Evaluation of febuxostat in treating diabetic kidney disease with hyperuricemia: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Front Med (Lausanne)
Lin M, Zhang H, Wu H, Zhao D, Nan Z, Fu Y.   +5 more
europepmc   +1 more source

Uric Acid-Lowering Therapy with Febuxostat in Patients with Chronic Heart Failure and Hyperuricemia: A Prospective and Observational Cohort Study [PDF]

Balkan Med J
Ke J, Qiu X, Wang M, Zeng H, Wang C, Zhang J, Zhu H, Gu J.   +7 more
europepmc   +1 more source

Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations [PDF]

, 2017
Hiroshi Miyata, Hiroshi Suzuki, Hirotaka Matsuo, Kimiyoshi Ichida, Tappei Takada, Yu Toyoda   +5 more
core   +1 more source

Contribution of Organic Anion Transporter 3 in Delayed Elimination of Methotrexate by Concomitant Administration of Febuxostat. [PDF]

Biopharm Drug Dispos
Ikemura K, Kobayashi S, Wang D, Okuda M.
europepmc   +1 more source

Population Pharmacodynamic Analysis for Exploration of the Factors Affecting Serum Uric Acid Levels in Hyperuricemic Patients who are Switched from Allopurinol to Febuxostat

, 2018
Takamitsu Ogata, Susumu Kaneshige, Koichi Matsuo, Naoya Matsunaga, Satoru Koyanagi, Shigehiro Ohdo, Hidetoshi Kamimura   +6 more
openalex   +2 more sources

Development and Validation of a Stability-Indicating RP-HPLC Method for the Determination of Febuxostat (a Xanthine Oxidase Inhibitor) [PDF]

, 2012
Mukthinuthalapati Mathrusri Annapurna, Sai Pavan Kumar Bandaru, Bukkapatnam Venkatesh, Chitaranjan Mohapatro   +3 more
openalex   +1 more source

Bioequivalence evaluation of generic febuxostat versus Feburic^® in healthy Chinese subjects: a randomized crossover study. [PDF]

BMC Pharmacol Toxicol
Wang F, Ye X, Li F, Kong H, Liao M, Kan M, Zhuang J, Wang A, Meng X.   +8 more
europepmc   +1 more source

Switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, may substantially reduce serum urate levels, through URAT1 inhibition, potentially without adversely affecting ABCG2 function: findings from the SWITCH SURI study. [PDF]

Front Endocrinol (Lausanne)
Osonoi T, Shirabe S, Saito M, Hosoya M, Watahiki N, Douguchi S, Ofuchi K, Katoh M.   +7 more
europepmc   +1 more source